IDXX
IDEXX LABORATORIES INC /DE
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$555.80
−0.81%Year over year
Reported trailing growth
- Revenue
- +12.8%
- EBITDA
- +15.4%
- EBIT
- +16.2%
- EPS
- +17.7%
- Free cash flow
- +61.5%
- Operating cash flow
- +51.0%
Forward estimates
Based on analyst estimates
- Revenue
- +10.3%
- EBITDA
- +13.4%
- EPS
- +13.8%
Three-year CAGR
- Revenue
- +8.5%
- EBITDA
- +14.1%
- EBIT
- +14.8%
- Net income
- +16.0%
- EPS
- +17.5%
- Free cash flow
- +38.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026